Anthera hits another setback as its Japanese partner quits on blisibimod

Damian Garde Anthera Pharmaceuticals is back on the hunt for a partner in Asia after Japanese drugmaker Zenyaku pulled the plug on the pair's collaboration, clouding the future ...

Endo’s generics unit Qualitest recalls gout, blood pressure meds

Eric Palmer Endo's Alabama plant where its Qualitest unit makes generics is recalling a couple of drugs, some for being outsized and off-color. FiercePharma News

Feds clamp a hold on Forum’s PhIII Alzheimer’s study following GI events

John Carroll The FDA has slammed the brakes on the late-stage Alzheimer's development program for encenicline after investigators reported a "small" number of serious ...

Takeda gets enough takers to complete $2.3B Actos settlement

Eric Palmer A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $ 2.3 billion offer to settle thousands of claims over the cancer risks ...

Why is Novartis’ Copaxone copy lagging? It’s all about coverage, analyst explains

Carly Helfand Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout Copaxone, though–and ...

UPDATED: Melinta’s CEO steps down amid a big Phase III push

Damian Garde Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech ...

FierceBiotech radio on GSK’s latest setback, Kyle Bass’ ‘truthful irrelevancy,’ and Horizon’s web presence

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug ...

Just wait, Perrigo investor urges. We can get the same return–without a Mylan deal

Carly Helfand All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli ...

Horizon steps up its official Depomed pursuit with campaign website

Carly Helfand Horizon Pharma has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed, including a letter related to its efforts to call ...

Next-gen antibody experts at AnaptysBio file $86M IPO

John Carroll Up to now, San Diego-based AnaptysBio has raised close to $ 49 million in cash directly from collaborators looking to the antibody shop to use their technology to create ...

UPDATED: On the ropes, GlaxoSmithKline admits to another PhIII debacle

John Carroll GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk ...

Novartis CEO: Payers not sold on performance pricing yet, but that’ll change

Tracy Staton Novartis CEO Joe Jimenez sees a couple of rays of hope for drug spending–and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing ...
Page 2 of 41234
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS